Alloin
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Alloin
- DrugBank Accession Number
- DB15477
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
- Weight
- Average: 418.398
Monoisotopic: 418.126382288 - Chemical Formula
- C21H22O9
- Synonyms
- Aloin
- Aloin, Cape
- Aloin, curaco
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Alloin. Aclidinium The therapeutic efficacy of Alloin can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Alloin can be decreased when used in combination with Alfentanil. Amantadine The therapeutic efficacy of Alloin can be decreased when used in combination with Amantadine. Amiloride The risk or severity of dehydration can be increased when Amiloride is combined with Alloin. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aid-lax Tab Alloin (12 mg / tab) + Frangula purshiana bark (30 mg / tab) + Phenolphthalein (100 mg / tab) + Sodium taurocholate (60 mg / tab) Tablet Oral Nobel Pharm Enr. 1989-12-31 1997-07-31 Canada Alsiline Alloin (12 mg / tab) + Frangula purshiana bark (30 mg / tab) + Phenolphthalein (100 mg / tab) + Sodium taurocholate (60 mg / tab) Tablet Oral Alsi Cie Ltee 1978-12-31 1997-08-08 Canada Bicholate Lilas Tab Alloin (12 mg) + Frangula purshiana bark (30 mg) + Phenolphthalein (100 mg) + Sodium taurocholate (60 mg) Tablet Oral Sabex Inc 1991-12-31 1997-10-10 Canada Bilex Tab Alloin (12 mg) + Frangula purshiana bark (30 mg) + Phenolphthalein (100 mg) + Sodium taurocholate (60 mg) Tablet Oral Biodo Enrg 1978-12-31 1997-10-10 Canada Carters Little Pills Tab Alloin (8 mg / tab) + Phenolphthalein (16 mg / tab) Tablet Oral Carter Products, Division Of Carter Wallace Ns Inc. 1978-12-31 1997-08-14 Canada
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- W41H6S09F4
- CAS number
- 8015-61-0
- InChI Key
- AFHJQYHRLPMKHU-CGISPIQUSA-N
- InChI
- InChI=1S/C21H22O9/c22-6-8-4-10-14(21-20(29)19(28)17(26)13(7-23)30-21)9-2-1-3-11(24)15(9)18(27)16(10)12(25)5-8/h1-5,13-14,17,19-26,28-29H,6-7H2/t13-,14?,17-,19+,20-,21+/m1/s1
- IUPAC Name
- 1,8-dihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-9,10-dihydroanthracen-9-one
- SMILES
- OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(CO)C=C2O
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.63 mg/mL ALOGPS logP -0.49 ALOGPS logP 0.41 Chemaxon logS -2.2 ALOGPS pKa (Strongest Acidic) 8.31 Chemaxon pKa (Strongest Basic) -2.9 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 9 Chemaxon Hydrogen Donor Count 7 Chemaxon Polar Surface Area 167.91 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 103.79 m3·mol-1 Chemaxon Polarizability 40.97 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0ldi-0061900000-2145c3838ca819834f50 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-02ta-0934500000-f6af1d749c4027863b2e Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0f79-0195500000-a6550d03249b53b8a18f Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-067j-0039100000-9bc800c36392d3423323 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-066r-1192000000-1703cf42955fae25a516 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4s-1395000000-ef0034ed0803e1364b50 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at August 30, 2019 15:38 / Updated at June 12, 2020 16:53